CNBX Pharmaceuticals Inc. (CNBX)
OTCMKTS · Delayed Price · Currency is USD
0.0004
0.00 (0.00%)
Aug 15, 2025, 3:59 PM EDT
CNBX Pharmaceuticals Employees
CNBX Pharmaceuticals had 2 employees as of August 31, 2024. The number of employees did not change compared to the previous year.
Employees
2
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$112,226
Market Cap
123.27K
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Aug 31, 2024 | 2 | 0 | - |
Aug 31, 2023 | 2 | -3 | -60.00% |
Aug 31, 2022 | 5 | -5 | -50.00% |
Aug 31, 2021 | 10 | 1 | 11.11% |
Aug 31, 2020 | 9 | -2 | -18.18% |
Aug 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Aug 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Aug 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Aug 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Aug 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Tian'an Technology Group | 8 |
Elite Pharmaceuticals | 68 |
Glass House Brands | 374 |
American Oncology Network | 1,914 |
Northwest Biotherapeutics | 25 |
CytoDyn | 13 |
Silence Therapeutics | 116 |
Longduoduo Company | 49 |
CNBX Pharmaceuticals News
- 2 years ago - Cannabis REITs: Smoked Out - Seeking Alpha
- 3 years ago - CNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza Biopharma - PRNewsWire
- 3 years ago - CNBX Files New PCT Patent Application For Cannabinoids-Based Neoadjuvant Cancer Therapy - PRNewsWire
- 3 years ago - CNBX Patent Application "Composition and Method for Treating Cancer with Cannabinoids" Enters National Phase in US and Israel - PRNewsWire
- 3 years ago - CNBX Peer-reviewed Study: "Possible Future Therapeutic Value" for CNBX Proprietary Drug Candidate - PRNewsWire
- 3 years ago - CNBX Pharmaceuticals Announces New Patent Granted in Australia - PRNewsWire
- 3 years ago - CNBX Pharmaceuticals Granted Patent in Hong Kong - PRNewsWire
- 3 years ago - Cannabics Pharmaceuticals Changes Name to CNBX Pharmaceuticals - PRNewsWire